Tirzepatide is making billions, but patients still can’t get coverage
I saw an industry projection saying tirzepatide could become the highest-selling drug in the world in 2026, with estimated revenue around $45 billion.
That’s wild when you think about how many people still can’t access it because their insurance plan excludes weight-loss medications.
At this point, it’s clearly not some experimental niche product with uncertain demand. The demand is obvious, the revenue is enormous, and the clinical interest is everywhere. Yet for obesity treatment, coverage is still inconsistent or completely unavailable for a lot of patients.
That makes the access issue feel less like a medical question and more like a pricing, insurance, and policy problem.
How do people think this changes over the next few years — do insurers eventually start covering obesity medications more broadly, or does this stay mostly pay-out-of-pocket for anyone without the “right” diagnosis?